Search Results 61-70 of 176 for 検索エンジンのソースコード 🔍 www.81g.net

  1. Center for Cell Signaling in Gastroenterology (C-SiG)

    The Center for Cell Signaling in Gastroenterology (C-SiG) at Mayo Clinic studies the signaling pathways in gastrointestinal cells to treat GI diseases.

  2. Uncovering the Signaling Events Underlying the Development and Progression of Pancreatic Cancer - Tumor Development, Immunology and Progression Laboratory - Mayo Clinic Research

    The Tumor Development, Immunology & Progression Lab of Peter Storz, Ph.D., at Mayo Clinic studies cell signaling events, pancreatic cancer development ...

  3. Csf Leak Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess for changes in the structure and function of the optic nerve caused by changes in cerebrospinal fluid pressure. Efficacy ...

  4. Regulation of FIH Expression in Renal Cancer - Tumor Angiogenesis and Vascular Biology Laboratory - Mayo Clinic Research

    The Mukhopadhyay Tumor Angiogenesis and Vascular Biology Lab at Mayo Clinic is studying transcriptional activity in renal cancer.

  5. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  6. Biomarkers for Cancer Early Detection and Survival Prediction Study - Hepatobiliary Cancer Laboratory - Mayo Clinic Research

    The Roberts Hepatobiliary Cancer Lab at Mayo Clinic is studying biomarkers for early detection of hepatocellular carcinoma and survival prediction.

  7. Finding the "G" that Increases Risk of Certain Brain Tumors

    People who carry a "G" instead of an "A" at a specific spot in their genetic code have a sixfold higher risk of developing certain types of brain tumors.

  8. Daniel S. Yip, M.D. - Mayo Clinic Faculty Profiles

    Mayo Clinic researcher Daniel S. Yip, M.D., studies heart failure, mechanical circulatory support and heart transplants.

  9. Aniket A. Saoji, Ph.D. - Mayo Clinic Faculty Profiles

    Learn more about the research interests of Aniket A. Saoji, Ph.D., a Mayo Clinic audiologist specializing in cochlear implants.

  10. A Study of TAK-981 in Combination with Rituximab in Participants with Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

    A Study of TAK-981 in Combination with Rituximab in Participants with Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL).